Assessing bleeding risk in atrial fibrillation with the HAS-BLED and ORBIT scores: Clinical application requires focus on the reversible bleeding risk factors

European Heart Journal

Volumn 36, Issue 46, 2015, Pages 3265-3267

  Lip, Gregory Y H ^a,b   Lane, Deirdre A ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b AALBORG UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALCOHOL; HEMOGLOBIN; NONSTEROID ANTIINFLAMMATORY AGENT; WARFARIN; ANTICOAGULANT AGENT;

ACUTE CORONARY SYNDROME; ALCOHOL CONSUMPTION; ANEMIA; ANTICOAGULATION; ATRIAL FIBRILLATION; BLEEDING; BLEEDING TENDENCY; BLOOD PRESSURE REGULATION; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE ASSESSMENT; CHADS2 SCORE; CLINICAL ASSESSMENT TOOL; CLINICAL FEATURE; DISEASE PREDISPOSITION; GOOD CLINICAL PRACTICE; HAS BLED SCORE; HUMAN; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; KIDNEY FUNCTION; LIVER FUNCTION; ORBIT SCORE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; THROMBOEMBOLISM; CEREBROVASCULAR ACCIDENT; CHEMICALLY INDUCED; ORBIT;

ANTICOAGULANTS; ATRIAL FIBRILLATION; HEMORRHAGE; HUMANS; ORBIT; RISK ASSESSMENT; RISK FACTORS; STROKE;

EID: 84951170841     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehv415     Document Type: Review

References (14)

1. De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, Baigent C, Huber K, Jespersen J, Kristensen SD, Lip GY, Morais J, Rasmussen LH, Siegbahn A, Verheugt FW, Weitz JI. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESCWorking Group on Thrombosis-Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013;110:1087-1107.
2. Gallego P, Roldan V, Marin F, Romera M, Valdes M, Vicente V, Lip GY. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. Thromb Haemost 2013;110:1189-1198.
3. Lip GY, Andreotti F, Fauchier L, Huber K, Hylek E, Knight E, Lane D, Levi M, Marin F, Palareti G, Kirchhof P. Bleeding risk assessment and management in atrial fibrillation patients. Executive Summary of a Position Document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis. Thromb Haemost 2011;106:997-1011.
4. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel userfriendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010;138:1093-1100.
5. Lip GY, Banerjee A, Lagrenade I, Lane DA, Taillandier S, Fauchier L. Assessing the risk of bleeding in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation project. Circ Arrhythm Electrophysiol 2012;5:941-948.
6. Apostolakis S, Lane DA, Guo Y, Buller H, Lip GY. Performance of the HEMORR (2) HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study. J Am Coll Cardiol 2012;60:861-867.
7. Roldan V, Marin F, Fernandez H, Manzano-Fernandez S, Gallego P, Valdes M, Vicente V, Lip GY. Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a 'real-world' population with atrial fibrillation receiving anticoagulant therapy. Chest 2013;143:179-184.
8. Kooiman J, van Hagen N, Iglesias Del Sol A, Planken EV, Lip GY, van der Meer FJ, Cannegieter SC, Klok FA, Huisman MV. The HAS-BLED score identifies patients with acute venous thromboembolism at high risk of major bleeding complications during the first six months of anticoagulant treatment. PLoS One 2015;10:e0122520.
9. Smith JG, Wieloch M, Koul S, Braun OO, Lumsden J, Rydell E, Ohman J, Schersten F, Svensson PJ, van der Pals J. Triple antithrombotic therapy following an acute coronary syndrome: prevalence, outcomes and prognostic utility of the HAS-BLED score. Euro Intervention 2012;8:672-678.
10. Omran H, Bauersachs R, Rubenacker S, Goss F, Hammerstingl C. The HAS-BLED score predicts bleedings during bridging of chronic oral anticoagulation. Results from the national multicentre BNK Online bRiDging REgistRy (BORDER). Thromb Haemost 2012;108:65-73.
11. O'Brien EC, Simon DN, Thomas LE, Hylek EM, Gersh BJ, Ansell JE, Kowey PR, Mahaffey KW, Chang P, Fonarow GC, Pencina MJ, Piccini JP, Peterson ED. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. Eur Heart J 2015;36:3258-3264.
12. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-891.
13. National-Institute-for-Health-and-Care-Excellence. Atrial fibrillation: the management of atrial fibrillation. (Clinical guideline 180.) 2014. http://guidance.nice.org. uk/CG180.
14. Ruiz-Ortiz M, Bertomeu V, Cequier A, Marin F, Anguita M. Validation of the SAMe-TT2R2 score in a nationwide population of nonvalvular atrial fibrillation patients on vitamin K antagonists. Thromb Haemost 2015;114; doi: 10.1160/TH15-02-0169.